Ribelles, Nuria

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Swain, S. M., Miles, D., Kim, S.-B., Im, Y.-H., Im, S.-A., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., et al. (2020) · The Lancet Oncology

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 922

ESMO guidance for reporting oncology real-world evidence (GROW)

Castelo-Branco, L., Pellat, A., Martins-Branco, D., Valachis, A., Derksen, J. W. G., Suijkerbuijk, K. P. M., Dafni, U., Dellaporta, T., Vogel, A., Prelaj, A., et al. (2023) · Annals of Oncology

Meta-analysis and systematic reviewsClinical practice guidelines implementation

Cited by 247